Positive allosteric modulators of muscarinic M2 receptor

US10435403B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Henrik Teller · Schwaan, DE
• Alexander Straub · Wuppertal, DE
• Markus BRECHMANN · Marburg, DE
• Thomas Müller · Bonn, DE
• Mark Meininghaus · Wuppertal, DE
• Katrin Nowak-Reppel · Leverkusen, DE
• Hanna Tinel · Wuppertal, DE
• Klaus Münter · Mannheim, DE
• Daniela FLIEGNER · Berlin, DE
• Thomas MONDRITZKI · Essen, DE
• Melissa BOULTADAKIS ARAPINIS · Düsseldorf, DE
• Tobias Marquardt · Wuppertal, DE
• Alexandros Vakalopoulos · Hilden, DE
• Anne-Sophie REBSTOCK · Écully, FR
• Matthias Beat WITTWER · Riehen, CH

Key dates

• Filing date: Jun 6, 2016
• Grant date: Oct 8, 2019
• Expiry date: Jun 6, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.